OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free CVSI Stock Alerts $0.04 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0452-Week Range$0.03▼$0.06Volume80,457 shsAverage Volume227,633 shsMarket Capitalization$6.19 millionP/E Ratio1.90Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get CV Sciences alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About CV Sciences Stock (OTCMKTS:CVSI)CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Read More CVSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVSI Stock News HeadlinesApril 1, 2024 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | investorplace.comCVSI Stock Earnings: CV Sciences Reported Results for Q4 2023April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 28, 2024 | prnewswire.comCV Sciences, Inc. Reports Fiscal Year-End 2023 Financial ResultsMarch 27, 2024 | wsj.comCV Sciences Inc.March 26, 2024 | finance.yahoo.comCV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsMarch 21, 2024 | prnewswire.comCV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024February 22, 2024 | benzinga.comCV Sciences Stock (OTC:CVSI), Short Interest ReportApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 12, 2023 | finance.yahoo.comCV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European DistributionNovember 15, 2023 | nz.finance.yahoo.comThe Best Shampoo for Thinning Hair We Tested Is 30% Off Right NowNovember 15, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | benzinga.comHemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%November 14, 2023 | msn.comCV Sciences GAAP EPS of $0.00, revenue of $4.09MNovember 14, 2023 | finance.yahoo.comCV Sciences, Inc. Reports Third Quarter 2023 Financial ResultsNovember 12, 2023 | morningstar.comCV Sciences Inc CVSINovember 9, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023September 5, 2023 | finance.yahoo.comCV Sciences, Inc. Launches Reserve Sleep GummiesAugust 15, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q2 2023 Earnings Call TranscriptAugust 14, 2023 | seekingalpha.comCV Sciences GAAP EPS of -$0.01, revenue of $4MAugust 14, 2023 | benzinga.comPublicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To KnowAugust 14, 2023 | finance.yahoo.comCV Sciences, Inc. Reports Second Quarter 2023 Financial ResultsAugust 1, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE SECOND QUARTER 2023 RESULTS ON AUGUST 14, 2023July 8, 2023 | finance.yahoo.comCVSI - CV Sciences, Inc.June 1, 2023 | finance.yahoo.comCV Sciences to Participate in LD Micro Invitational ConferenceMay 15, 2023 | msn.comCV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To KnowMay 15, 2023 | finance.yahoo.comCV Sciences, Inc. Reports First Quarter 2023 Financial ResultsSee More Headlines Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CUSIPN/A CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees42Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.02 Trailing P/E Ratio1.90 Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net Margins19.38% Pretax Margin19.34% Return on Equity80.98% Return on Assets30.87% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio0.37 Sales & Book Value Annual Sales$16 million Price / Sales0.39 Cash Flow$0.02 per share Price / Cash Flow1.89 Book Value$0.02 per share Price / Book1.90Miscellaneous Outstanding Shares163,230,000Free Float161,106,000Market Cap$6.19 million OptionableNot Optionable Beta0.62 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Joseph D. Dowling (Age 67)CEO, Secretary & Director Comp: $298.98kMr. Joerg Grasser (Age 49)Chief Financial Officer Comp: $210.47kMr. Tim HitchmanVice President of OperationsMr. Jesse KaragianesSenior Vice President of Revenue GrowthMs. Alyssa DunnOperations ManagerKey CompetitorsCadrenal TherapeuticsNASDAQ:CVKDAinosNASDAQ:AIMDXenetic BiosciencesNASDAQ:XBIOFirst Wave BioPharmaNASDAQ:FWBIProtagenic TherapeuticsNASDAQ:PTIXView All Competitors CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed in 2024? CV Sciences' stock was trading at $0.0354 at the beginning of 2024. Since then, CVSI shares have increased by 7.2% and is now trading at $0.0380. View the best growth stocks for 2024 here. Are investors shorting CV Sciences? CV Sciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 27,600 shares, an increase of 305.9% from the March 15th total of 6,800 shares. Based on an average daily trading volume, of 818,700 shares, the short-interest ratio is currently 0.0 days. View CV Sciences' Short Interest. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($0.01) EPS for the quarter. The business had revenue of $3.80 million for the quarter. CV Sciences had a trailing twelve-month return on equity of 80.98% and a net margin of 19.38%. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), Organigram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA). How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CVSI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
